Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to “Sell”

Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts have also commented on the company. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Zacks Research downgraded Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Guggenheim reduced their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.80.

Monte Rosa Therapeutics Stock Down 2.7%

Shares of NASDAQ GLUE opened at $15.63 on Friday. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -33.98 and a beta of 1.63. The company’s 50-day simple moving average is $19.62 and its 200-day simple moving average is $14.84. Monte Rosa Therapeutics has a 52-week low of $3.50 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $2.78 million for the quarter, compared to analyst estimates of $17.09 million. Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%. Equities research analysts anticipate that Monte Rosa Therapeutics will post -1.49 EPS for the current fiscal year.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the completion of the sale, the insider directly owned 22,693 shares in the company, valued at $410,743.30. This represents a 52.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at $10,993,400.32. This represents a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 36,771 shares of company stock valued at $693,692. Insiders own 6.90% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently made changes to their positions in GLUE. GAMMA Investing LLC acquired a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $30,000. Nisa Investment Advisors LLC raised its position in shares of Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in Monte Rosa Therapeutics in the fourth quarter worth approximately $63,000. Finally, Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics in the third quarter worth approximately $32,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.